HPV vaccination: The most pragmatic cervical cancer primary prevention strategy  by Sankaranarayanan, Rengaswamy
International Journal of Gynecology and Obstetrics 131 (2015) S33–S35
Contents lists available at ScienceDirect
International Journal of Gynecology and Obstetrics
j ourna l homepage: www.e lsev ie r .com/ locate / i jgoREPRODUCTIVE HEALTHHPV vaccination: The most pragmatic cervical cancer primary
prevention strategyRengaswamy Sankaranarayanan ⁎
International Agency for Research on Cancer, Lyon, France⁎ International Agency for Research on Cancer, 150 Cou
Cedex 08, France. Tel.: +33 472 73 85 99; fax: +33 472 7
E-mail address: sankarr@iarc.fr.
http://dx.doi.org/10.1016/j.ijgo.2015.02.014
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on





ScreeningThe evidence that high-risk HPV infections cause cervical cancers has led to two new approaches for cervical can-
cer control: vaccination to prevent HPV infections, and HPV screening to detect and treat cervical precancerous
lesions. Two vaccines are currently available: quadrivalent vaccine targeting oncogenic HPV types 16, 18, 6,
and 11, and bivalent vaccine targeting HPV 16 and 18. Both vaccines have demonstrated remarkable immunoge-
nicity and substantial protection against persistent infection and high-grade cervical cancer precursors caused by
HPV 16 and 18 inHPV-naïvewomen, and have the potential to prevent 70% of cervical cancers in adequately vac-
cinated populations. HPV vaccination is now implemented in national programs in 62 countries, including some
low- and middle-income countries. The early ﬁndings from routine national programs in high-income countries
are instructive to encourage low- andmiddle-income countries with a high risk of cervical cancer to roll out HPV
vaccination programs and to introduce resource-appropriate cervical screening programs.
© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cervical cancer is the fourthmost common cancer in the world with
an estimated 528 000 new cases and 267 000 cervical cancer deaths
annually, of which 445 000 new cases and 230 000 deaths occur low-
and middle-income countries (LMICs) in Sub-Saharan Africa, Central
and South America, Asia, and Oceania [1]. Lack of screening programs
and high prevalence of HPV infection in the population are the major
factors responsible for the high risk observed in LMICs. The knowledge
that persistent infectionwith one of the oncogenic HPV types is the nec-
essary cause for cervical cancer has led toHPV vaccination andHPV test-
ing as emerging strategies for prevention and early detection of cervical
cancer. However, these are yet to be implemented in national programs
in many LMICs, where they are most needed. The overarching role of
HPV vaccination as themost pragmatic and feasible primary prevention
strategy for cervical cancer is brieﬂy discussed here.
2. HPV infection and cervical cancer
Cervical cancer is a rare long-term outcome of infection with a high-
risk HPV type (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68),
particularly HPV 16. Peak frequency of HPV infection occurs in adoles-
cence and early adulthood, with a life-time probability of infection ofrs Albert Thomas, 69372, Lyon
3 85 18.
behalf of International Federation ofapproximately 80%− 90%. The frequency of incident HPV infections de-
clines steadily with age. HPV infection persists in 5% − 15% of the
infectedwomen,while 85%− 90% of the infections becomeundetectable
within two years. Thosewith persistent HPV infection are at high risk for
cervical cancer and HPV 16 and 18 cause 70%− 75% of the cervical can-
cer cases across theworld [2,3]. HIV-infectedwomen are at higher risk of
HPV infection despite the advent of antiretroviral therapy (ART) and are,
therefore, at high risk for cervical neoplasia.
The natural history of cervical cancer involves four stages, namelyHPV
infection of the transformation zone (TZ), HPV infection persistence, clon-
al expansion of HPV infected cells to high-grade cervical intraepithelial
neoplasia (CIN 3) or adenocarcinoma in situ (AIS), and their progression
to invasive cancer [2]. Minor cellular abnormalities, such as atypical squa-
mous cells of undetermined signiﬁcance (ASCUS), low-grade squamous
intraepithelial lesions (LSIL), or atypical glandular cells of undetermined
signiﬁcance (AGUS), on cytology or low-grade CIN (CIN1) on histology
may be observedwithinmonths following incident and transient HPV in-
fections. With the clearance of infection in the vast majority (N80%), the
low-grade lesions resolve [2]. CIN 3 and AIS are considered to be the
real precursors of cervical cancer and 40% − 50% of untreated lesions
may progress to cancer over a 5− 30-year period [4–6]. The duration be-
tween HPV infection and developing CIN 3 is shorter than the time be-
tween CIN 3 developing into invasive cancer. Although healthy
lifestyles, improved socioeconomic status, awareness, empowerment of
women with education and better social status, male circumcision, and
improved hygiene contribute to reducing risk of cervical cancer,
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prevention strategy [7,8].
3. Prevention
The fact that high-risk HPV infections cause almost all cervical cancers
has led to two new approaches for cervical cancer control: primary pre-
vention by vaccination to prevent HPV infections in pre-adolescents and
adolescents (9−18-year-old girls) and early detection of cervical precan-
cerous lesions such as CIN 3 and AIS by HPV screening in women aged
30 years and older. Two recombinant HPV vaccines containing viral-like
particles (VLP) are currently available: quadrivalent vaccine targeting on-
cogenicHPV types 16, 18, 6, and11, andbivalent vaccine targetingHPV16
and 18. Both vaccines have demonstrated remarkable immunogenicity
and substantial protection against persistent infection, CIN 3, and anal
intraepithelial neoplasia caused by the vaccine-targeted HPV types in
women aged 15–26 years naïve to the corresponding type at the time
of vaccination. Both vaccines have the potential to prevent 70% of cervical
cancers in adequately vaccinated populations [9]. Efﬁcacy against persis-
tent infectionwith vaccine-targetedHPV types and related CIN 3 frequen-
cy in HPV-naïve populations in Phase III clinical trials exceeded 99% [9].
Immunogenicity bridging studies demonstrated strong immunogenicity
and excellent safety in pre-adolescence, although clinical trials did not in-
clude pre-adolescent girlswho are the primary target populations for cur-
rent national immunization programs. The evidence on safety and
efﬁcacy of the vaccines in clinical trials, demonstration projects, and rou-
tine public health settings all strongly support the introduction of HPV
vaccination in national immunization programs. Mild to moderate
injection-site pain, headache, and fatiguewere themost commonadverse
events following HPV vaccination.
HPV vaccination is currently part of the national immunization pro-
gram in 62 countries targeting pre-adolescent and adolescent girls and
“catch-up” immunization of older cohorts with upper age limits up to
26 years. Cost-effectiveness studies support the implementation of
HPV vaccination of pre-adolescent/adolescent girls before sexual onset
including LMICs provided the vaccines are affordable; the cost-
effectiveness in LMICs is heavily inﬂuenced by the unit cost of the vac-
cine [7,8,10–12]. Difﬁculty in procuring vaccines due to high costs is a
major challenge, although in recent years vaccine costs have been com-
ing down. From a realistic implementation perspective, government
commitment, procuring HPV vaccines at affordable prices (through
tiered pricing or negotiated pricing, or through the Gavi vaccine alliance
or the PAHO revolving fund), using the recently recommended two
dose schedules as well as education of the community at large to create
awareness about the safety and efﬁcacy are critical to introduce HPV
vaccination in national immunization programs in LMICs.
It is estimated that full vaccination of a cohort of 58 million 12-year-
old girls in 179 countries for which UN population estimates are avail-
able will prevent 690 000 cervical cancer cases and 420 000 deaths at
a net cost of US $4 billion; HPV vaccination was cost-effective (with
every disability-adjusted life-year averted costing less than the per
capita gross domestic product of the country) in 156 (87%) of the 179
countries [8]. Although studies differ in their conclusions about the op-
timal age for catch-up vaccination, a catch-up round for young adoles-
cent girls (12–15 years), whose future access to screening is uncertain
in LMICs, is worth considering and 16%− 20% of HPV 16/18 protection
from vaccination is attributed to catch-up vaccination strategy [13].
Only a few cost-effectiveness studies indicate that including boys in
HPV vaccination programs would be a cost-effective strategy [7,14].
Vaccinating with fewer than three doses will lower costs, ease logistics
of vaccine delivery, increase accessibility, and improve adherence to vacci-
nation. Immunogenicity following two doses in adolescent girls has been
shown to be non-inferior to that of a three-dose course in the age group
where efﬁcacy against persistent infection and pre-cancerous lesions has
been demonstrated [15–19]. Protection in terms of persistent infection of
vaccine-targetedHPV types among a small sample ofwomenwho receivedtwodoses, or a single dose only bydefault, has been reported [20]. Based on
ﬁndings that immunogenicity of two doses is comparable to three doses in
9− 14-year-old girls, the European Medical Agency and 10 countries in
Central and North America, Africa, and Asia have licensed the use of two-
dose regimens. Whereas most countries continue to use the three-dose
schedule in their national immunization programs, based on the recent re-
search evidence, a two-dose regimen is being used in some countries such
as Canada, Chile, Colombia, Mexico, South Africa, and Switzerland, and
Englandwill switch over to a two-dose schedule from September 2014 on-
ward. The guidelines in England for switching over to two-dose regimen
suggest that the ﬁrst dose can be given at any time during school year 8
(12− 13-year-old girls) followed by aminimumof sixmonths and amax-
imum of 24 months between doses; for operational purposes a 12-month
gap between the ﬁrst and second doses has been recommended.
Among LMICs, Bhutan, Malaysia, Uzbekistan, Fiji, Rwanda [21], South
Africa, Zambia, Uganda, Panama, Mexico, Brazil, Chile, Argentina,
Colombia, Peru, Uruguay, and Paraguay have implemented HPV vaccina-
tion as part of a national immunization program. High coverage of the
target populations (N90% third dose or second dose) and excellent safety
proﬁle have been observed in Bhutan, Malaysia, Rwanda, Brazil, and
South Africa among others. Ten LMICs (nine in Sub-Saharan Africa, i.e.
Ghana, Kenya, Madagascar, Malawi, Mozambique, Niger, Sierra Leone,
Tanzania, and Zimbabwe, as well as Laos in Asia) have introduced HPV
vaccination demonstration projects supported by GAVI. Uganda,
Rwanda, and Uzbekistan are currently receiving support from GAVI
alliance for HPV vaccination in their wider national immunization pro-
grams. The introduction ofHPVvaccination as part of national immuniza-
tion programs in some LMICs has happened in spite of anti-vaccination
campaigns in different countries. Indeed, one of the real challenges at
present seems to be the signiﬁcant anti-vaccine propaganda, political
andmedia frenzies spreadingmisinformation, and exaggerated and erro-
neous adverse event coverage in many countries.
Preliminary evaluation of HPV vaccination programs, in some high-
income countries where vaccination was introduced 4 or 5 years ago,
has shown that the frequency of vaccine-targeted HPV infections, pre-
cancerous lesions, and genital warts associated with vaccine- included
HPV types among vaccinated cohorts is declining [22–24]. In April
2007, Australia introduced quadrivalent HPV vaccination for 12− 13-
year-old girls through a school-based program followed by a catch-up
vaccination for 13− 26-year-olds via schools, community-based pro-
grams, and general practices during July to December 2009. Third-
dose coverage among the primary target group exceeded a modest
70%. A signiﬁcant decline in the prevalence of HPV types 16/18/6/11
after introduction of a national HPV vaccination program such as a
77% fall in prevalence of HPV vaccine-related infections, 90% reduction
in genital warts, and 48% reduction in CIN3/AIS lesions in the vaccine-
targeted age group has been reported in Australia [22], corresponding
to model-based projections made in 2007 [25]. In Scotland, a signiﬁcant
decline in HPV 16 and 18 prevalence was demonstrated among HPV-
vaccinated women (prevalence = 150/1100 [13.6%]) compared with
unvaccinated women (prevalence = 1018/3418 [29.5%]) in a cross-
sectional study involving 1000 women aged 20–21 years recruited an-
nually during 2009 − 2012 [24]. Six years from the introduction of
HPV vaccination in Denmark in 2006, the risk of atypia or worse lesions
and CIN2 and 3 lesions have signiﬁcantly declined among vaccinated
women; there is a 44% reduction in CIN2− 3 lesions among vaccinated
cohorts of women born during 1991 and 1992 and a 73% reduction in
CIN2− 3 lesions in the 1993–1994 birth cohorts [23].
4. Conclusion
After reviewing the evidence, WHO currently recommends a two-
dose HPV vaccination schedule for girls with a minimal interval of six
months between the doses, if vaccination is initiated prior to 15 years
of age; this interval may be extended to 12 months if this facilitates
vaccination [26]. This new recommendation on two doses makes
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able than a three-dose schedule. A three-dose schedule at 0, 1–2, and
6 months remains necessary if immunization is initiated after the girls’
15th birthday and for immunocompromised individuals, including
those known to be HIV infected.
The early ﬁndings on safety and intermediate endpoints from rou-
tine national programs in high-income countries are instructive to en-
courage LMICs with a high risk of cervical cancer to roll out HPV
vaccination programs to prevent cervical cancer and to introduce re-
source appropriate cervical screening programs taking into account
the post vaccination scenario of successive cohorts of women at low
risk for HPV infection and CIN as vaccination proceeds. High-income
countries eventually need to reorganize their existing screening pro-
grams to balance the overall costs of both vaccination and screening tak-
ing into account the challenges for cytology screening and colposcopy
triage in viewof the anticipated low frequency ofHPV infection anddys-
plastic changes due to both post vaccination immunogenicity and herd
immunity. Based on the anticipated impact of vaccination on the perfor-
mance of cytology, a changeover to HPV testing as the primary screen-
ing test followed by cytology triage (in view of the already built-up
cytology infrastructure in high- and in somemiddle-income countries),
later initiation of screening (at 30 or 35 years), and less frequent screen-
ing (e.g. one in 10 years or even a single round of screening in low- and
low-middle-income countries) is inevitable in due course. While HPV
vaccination will result in successive cohorts of women at low risk of
HPV infection and cervical neoplasia as vaccination progresses, screen-
ing will reduce the risk of cervical cancer deaths among targeted
women not yet protected by HPV vaccination or in women in whom
vaccination has failed. The timing of the effect of vaccination on cervical
screening will be country-speciﬁc and will depend on any catch-up
vaccination, variation in coverage, the impact of herd immunity, and
the age at which screening started.
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